Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44


Rising-frequency chirp stimulus to effectively enhance wave-I amplitude of auditory brainstem response.

Morimoto T, Fujisaka YI, Okamoto Y, Irino T.

Hear Res. 2019 Jun;377:104-108. doi: 10.1016/j.heares.2019.03.016. Epub 2019 Mar 22.


Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.

Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y.

Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.


An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.

Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, Kitamura H, Iwasa T, Nagashima F, Nakagawa K.

Cancer Chemother Pharmacol. 2018 Sep;82(3):511-519. doi: 10.1007/s00280-018-3618-4. Epub 2018 Jul 10.


Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.


Long non-coding RNA HOTAIR up-regulates chemokine (C-C motif) ligand 2 and promotes proliferation of macrophages and myeloid-derived suppressor cells in hepatocellular carcinoma cell lines.

Fujisaka Y, Iwata T, Tamai K, Nakamura M, Mochizuki M, Shibuya R, Yamaguchi K, Shimosegawa T, Satoh K.

Oncol Lett. 2018 Jan;15(1):509-514. doi: 10.3892/ol.2017.7322. Epub 2017 Nov 1.


Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.

Inoue J, Kanno A, Wakui Y, Miura M, Kobayashi T, Morosawa T, Kogure T, Kakazu E, Ninomiya M, Fujisaka Y, Umetsu T, Takai S, Nakamura T, Shimosegawa T.

Tohoku J Exp Med. 2017 Jan;241(1):21-28. doi: 10.1620/tjem.241.21.


PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.

Iwata T, Kondo Y, Kimura O, Morosawa T, Fujisaka Y, Umetsu T, Kogure T, Inoue J, Nakagome Y, Shimosegawa T.

Sci Rep. 2016 Dec 14;6:39296. doi: 10.1038/srep39296.


Small-cell Lung Cancer in a Young Adult Nonsmoking Patient with Ectopic Adrenocorticotropin (ACTH) Production.

Aoki M, Fujisaka Y, Tokioka S, Hirai A, Henmi Y, Inoue Y, Narabayashi K, Yamano T, Tamura Y, Egashira Y, Higuchi K.

Intern Med. 2016;55(10):1337-9. doi: 10.2169/internalmedicine.55.6139. Epub 2016 May 15.


Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy.

Inoue J, Kondo Y, Wakui Y, Kogure T, Morosawa T, Fujisaka Y, Umetsu T, Takai S, Nakamura T, Shimosegawa T.

Clin J Gastroenterol. 2016 Apr;9(2):93-8. doi: 10.1007/s12328-016-0631-1. Epub 2016 Feb 26.


Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular Carcinoma.

Kondo Y, Kimura O, Kogure T, Ninomiya M, Umezawa R, Sugawara T, Matsushita H, Jingu K, Nakagome Y, Iwata T, Morosawa T, Fujisaka Y, Iwasaki T, Shimosegawa T.

Tohoku J Exp Med. 2015 Dec;237(4):249-57. doi: 10.1620/tjem.237.249.


A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.

Kasuga A, Nakagawa K, Nagashima F, Shimizu T, Naruge D, Nishina S, Kitamura H, Kurata T, Takasu A, Fujisaka Y, Okamoto W, Nishimura Y, Mukaiyama A, Matsushita H, Furuse J.

Invest New Drugs. 2015 Oct;33(5):1058-67. doi: 10.1007/s10637-015-0270-2. Epub 2015 Aug 12.


Shifting hepatitis B virus genotypes of acute hepatitis B patients in northeast Japan.

Inoue J, Kondo Y, Umetsu T, Yamamoto T, Miura M, Mano Y, Kobayashi T, Obara N, Niitsuma H, Kogure T, Nakagome Y, Kimura O, Iwata T, Morosawa T, Fujisaka Y, Shimosegawa T.

J Med Virol. 2016 Jan;88(1):69-78. doi: 10.1002/jmv.24309.


Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells.

Kondo Y, Kimura O, Tanaka Y, Ninomiya M, Iwata T, Kogure T, Inoue J, Sugiyama M, Morosawa T, Fujisaka Y, Shimosegawa T.

J Virol. 2015 Jul;89(14):7016-27. doi: 10.1128/JVI.00716-15. Epub 2015 Apr 29.


Large cell neuroendocrine carcinoma of the lung with cancer-associated retinopathy.

Nakamura T, Fujisaka Y, Tamura Y, Tsuji H, Matsunaga N, Yoshida S, Imanishi M, Fujita K, Ikeda S, Oku H, Goto I, Ikeda T, Hanafusa T.

Case Rep Oncol. 2015 Mar 7;8(1):153-8. doi: 10.1159/000380943. eCollection 2015 Jan-Apr.


A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K.

Br J Cancer. 2015 Mar 3;112(5):819-24. doi: 10.1038/bjc.2015.10. Epub 2015 Feb 5.


Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.

Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K.

Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.


[Lung cancer: progress in diagnosis and treatments. Topics: II. Diagnosis and examination; 1. Training plan for oncology professionals].

Fujisaka Y, Nakagawa K.

Nihon Naika Gakkai Zasshi. 2014 Jun 10;103(6):1267-72. Review. Japanese. No abstract available.


Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K.

Invest New Drugs. 2014 Oct;32(5):946-54. doi: 10.1007/s10637-014-0112-7. Epub 2014 May 31.


An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.

Murakami H, Kurata T, Onozawa Y, Watanabe J, Ono A, Takahashi T, Yamamoto N, Fujisaka Y, Kiyota H, Hayashi H, Tanaka K, Nakagawa K, Kuroda S.

Cancer Chemother Pharmacol. 2014 Mar;73(3):623-30. doi: 10.1007/s00280-014-2388-x. Epub 2014 Jan 30.


Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.

Hayashi H, Okamoto I, Ueda S, Tanaka K, Okamoto K, Kawakami H, Nishina S, Takeda M, Fujisaka Y, Satoh T, Terao K, Nishimura Y, Doi K, Nakagawa K.

Anticancer Res. 2013 Dec;33(12):5699-705.


CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.

Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa K.

Br J Cancer. 2013 Nov 26;109(11):2803-9. doi: 10.1038/bjc.2013.588. Epub 2013 Oct 29.


[A case of liver cirrhosis due to non-alcoholic steatohepatitis complicated by myotonic dystrophy].

Ariake K, Miura M, Takahashi M, Ueno T, Sato S, Akada M, Maeda S, Fujisaka Y, Ohto T, Naito H.

Nihon Shokakibyo Gakkai Zasshi. 2013 Sep;110(9):1633-9. Japanese.


Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Cancer Sci. 2013 Apr;104(4):481-5. doi: 10.1111/cas.12105. Epub 2013 Mar 15.


[A case of huge papillary adenocarcinoma of the gallbladder with marked necrosis].

Onuma M, Miura M, Fujisaka Y, Zuguchi M, Asonuma S, Umemura T, Iioka Y, Outou T, Takahashi M, Naito H.

Nihon Shokakibyo Gakkai Zasshi. 2013 Jan;110(1):95-103. Japanese.


Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.

Hayashi H, Kurata T, Fujisaka Y, Kawakami H, Tanaka K, Okabe T, Takeda M, Satoh T, Yoshida K, Tsunoda T, Arao T, Nishio K, Nakagawa K.

Cancer Sci. 2013 Jan;104(1):98-104. doi: 10.1111/cas.12034. Epub 2012 Nov 8.


Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, Kaneda H, Tsurutani J, Nakagawa K.

Anticancer Res. 2012 May;32(5):1805-9.


First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.

Fujisaka Y, Onozawa Y, Kurata T, Yasui H, Goto I, Yamazaki K, Machida N, Watanabe J, Shimada H, Shi X, Boku N.

Invest New Drugs. 2013 Feb;31(1):108-14. doi: 10.1007/s10637-012-9809-7. Epub 2012 Mar 14.


Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Br J Cancer. 2011 Oct 25;105(9):1267-72. doi: 10.1038/bjc.2011.395. Epub 2011 Sep 29.


Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA.

Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.


Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K.

Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24. doi: 10.1016/j.bbrc.2011.03.002. Epub 2011 Mar 4.


A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.

Jpn J Clin Oncol. 2010 Aug;40(8):732-8. doi: 10.1093/jjco/hyq047. Epub 2010 Apr 29.


Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.

Fujisaka Y, Yamada Y, Yamamoto N, Shimizu T, Fujiwara Y, Yamada K, Tamura T, Watanabe H, Sun YN, Bass MB, Seki M.

Cancer Chemother Pharmacol. 2010 Oct;66(5):935-43. doi: 10.1007/s00280-010-1243-y. Epub 2010 Jan 28.


Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

Yamamoto N, Yamada Y, Fujiwara Y, Yamada K, Fujisaka Y, Shimizu T, Tamura T.

Jpn J Clin Oncol. 2009 Apr;39(4):260-6. doi: 10.1093/jjco/hyp006. Epub 2009 Mar 4.


[Case of successfully treated acute respiratory distress syndrome complicated by ureteral stones].

Chikuie N, Fujita K, Tabata E, Fujisaka Y, Takasu T, Ikeda S, Goto I, Hanafusa T.

Kansenshogaku Zasshi. 2008 Sep;82(5):455-60. Japanese.


Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T.

Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. Epub 2007 Jun 27.


Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, Tamura T.

Cancer Chemother Pharmacol. 2008 Mar;61(3):489-96. Epub 2007 May 5.


Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Sumi M, Ito Y, Kato T, Fujisaka Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T.

Jpn J Clin Oncol. 2007 Mar;37(3):175-80. Epub 2007 Apr 23.


A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N.

J Thorac Oncol. 2006 Nov;1(9):1002-9.


[A case of bullous pemphigoid associated with Pneumocystis pneumonia and Cytomegalovirus pneumonia].

Chikuie N, Ikeda S, Wakura D, Fujisaka Y, Fujita K, Takasu T, Goto I, Hanafusa T.

Nihon Kokyuki Gakkai Zasshi. 2006 Dec;44(12):1006-10. Japanese.


Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.

Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.

Jpn J Clin Oncol. 2006 Dec;36(12):768-74. Epub 2006 Nov 9.


Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.

Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Horiike A, Kodama T, Saijo N.

Jpn J Clin Oncol. 2006 Aug;36(8):477-82. Epub 2006 Aug 9.


Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.

Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, Tamura T.

Cancer Sci. 2005 Oct;96(10):721-8.


[International estimation of molecular target drug].

Fujisaka Y, Saijo N.

Nihon Rinsho. 2004 Jul;62(7):1225-31. Review. Japanese.


[Growth factor induced signal transduction in lung cancer].

Fujisaka Y, Saijo N.

Nihon Rinsho. 2002 May;60 Suppl 5:83-8. Review. Japanese. No abstract available.


Supplemental Content

Loading ...
Support Center